Insider Selling: Ainos (NASDAQ:AIMD) Director Sells $208,977.20 in Stock

Posted by George Bondi on May 30th, 2026

Ainos, Inc. (NASDAQ:AIMD – Get Free Report) Director Ting-Chuan Lee sold 109,988 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $1.90, for a total value of $208,977.20. Following the completion of the sale, the director owned 807,417 shares of the company’s stock, valued at $1,534,092.30. This represents a 11.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Ainos Trading Down 13.1%

NASDAQ AIMD opened at $2.38 on Friday. The stock has a 50-day simple moving average of $1.71 and a 200 day simple moving average of $1.83. The company has a market capitalization of $20.29 million, a PE ratio of -0.82 and a beta of 2.29. The company has a current ratio of 0.55, a quick ratio of 0.50 and a debt-to-equity ratio of 1.58. Ainos, Inc. has a 12 month low of $1.26 and a 12 month high of $4.50.

Ainos (NASDAQ:AIMD – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.41) EPS for the quarter. Ainos had a negative net margin of 11,912.10% and a negative return on equity of 160.55%.

Institutional Investors Weigh In On Ainos

Several large investors have recently modified their holdings of AIMD. DRW Securities LLC increased its holdings in shares of Ainos by 272.6% in the fourth quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock worth $109,000 after acquiring an additional 48,439 shares in the last quarter. Two Sigma Investments LP bought a new stake in shares of Ainos in the third quarter worth about $80,000. Mariner LLC bought a new stake in shares of Ainos in the fourth quarter worth about $37,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Ainos by 13.1% in the fourth quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock worth $109,000 after acquiring an additional 7,700 shares in the last quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

View Our Latest Analysis on AIMD

About Ainos

(Get Free Report)

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.